TSE:HEXOHexo Stock Price, Forecast & News

C$1.00

+0.06 (+6.38 %)

(As of 06/4/2020 11:21 AM ET)

Add

Compare

Today's Range

C$0.94

Now: C$1.00▼

C$1.03

50-Day Range

C$0.62

MA: C$0.75▼

C$1.09

52-Week Range

C$0.50

Now: C$1.00▼

C$9.02

Volume6.60 million shs

Average Volume4.07 million shs

Market CapitalizationC$407.86 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

HEXO Corp., through its subsidiary, HEXO Operations Inc., produces, markets, and sells cannabis in Canada. The company offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. It provides its products under the HEXO and Hydropothecary brand names. The company serves medical and adult-use markets. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. is headquartered in Gatineau, Canada.

Beat the Market (BTM) Rank^™

2.9 Analyst's Opinion

Consensus Rating
Hexo has received a consensus rating of Hold. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of C$1.37, Hexo has a potential upside of 37.1% from its current price of C$1.00.
Amount of Analyst Coverage
Hexo has received no research coverage in the past 90 days.

2.4 Community Rank

Outperform Votes
Hexo has received 47 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Hexo has received 51 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Hexo has received 52.04% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Hexo and other stocks. Vote “Outperform” if you believe HEXO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HEXO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Hexo does not currently pay a dividend.
Dividend Growth
Hexo does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hexo insiders have not sold or bought any company stock.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Hexo are expected to grow in the coming year, from C($0.11) to C$0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Hexo is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hexo is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Due to a projected decrease in earnings for Hexo, their PEG ratio cannot be calculated.
Price to Book Value per Share Ratio
Hexo has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.31 out of 5 stars

Industry, Sector and Symbol

Stock Exchange TSE

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolTSE:HEXO

Previous Symbol

CUSIPN/A

CIKN/A

Webhexo.com

Phone844-406-1852

Debt

Debt-to-Equity Ratio20.98

Current Ratio3.77

Quick Ratio1.80

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E Growth-0.02

Sales & Book Value

Annual SalesC$59.95 million

Price / Sales6.80

Cash FlowC$0.28 per share

Price / Cash Flow3.53

Book ValueC$1.83 per share

Price / Book0.55

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees374

Outstanding Shares407,856,000

Market CapC$407.86 million

Next Earnings DateN/A

OptionableOptionable

Receive HEXO News and Ratings via Email

Sign-up to receive the latest news and ratings for HEXO and its competitors with MarketBeat's FREE daily newsletter.

Hexo (TSE:HEXO) Frequently Asked Questions

How has Hexo's stock been impacted by COVID-19 (Coronavirus)?

Hexo's stock was trading at C$1.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HEXO shares have decreased by 21.3% and is now trading at C$1.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Hexo?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hexo in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Hexo.

What price target have analysts set for HEXO?

4 Wall Street analysts have issued 1 year target prices for Hexo's shares. Their forecasts range from C$0.75 to C$2.00. On average, they expect Hexo's stock price to reach C$1.37 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price. View analysts' price targets for Hexo.

Has Hexo been receiving favorable news coverage?

News stories about HEXO stock have trended extremely negative on Thursday, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hexo earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the stock's share price in the next several days. View the latest news aboutHexo.

Who are some of Hexo's key competitors?

Some companies that are related to Hexo include Knight Therapeutics (GUD), Ecofibre (EOF), HLS Therapeutics (HLS), OrganiGram (OGI), Next Science (NXS), ICC Labs (ICC), Amryt Pharma (AMYT), Benchmark (BMK), ESSA Pharma (EPI), Probiotec (PBP), Green Organic Dutchman (TGOD), WeedMD (WMD), CannTrust (TRST), Supreme Cannabis (FIRE) and Shield Therapeutics (STX). View all competitors.

What other stocks do shareholders of Hexo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hexo investors own include Aurora Cannabis (ACB), Aurora Cannabis (ACB), Canopy Growth (CGC), Canopy Growth (WEED), Aphria (APHA), Green Organic Dutchman (TGOD), Curaleaf (CURLF), Tilray (TLRY), Charlotte's Web (CWBHF) and KushCo (KSHB).

Who are Hexo's key executives?

Hexo's management team includes the following people:

Mr. Sebastien G. St-Louis, Co-Founder, Pres, CEO & Director (Age 35)
Mr. Adam Miron, Co-founder, Chief Brand Officer & Director (Age 35)
Mr. Ed Chaplin, CFO & Corp. Sec. (Age 49)
Mr. James McMillan, VP of Bus. Devel. (Age 51)
Dr. Terence Lake DVM, Vice-Pres of Corp. & Social Responsibility

What is Hexo's stock symbol?

Hexo trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HEXO."

How do I buy shares of Hexo?

Shares of HEXO and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Hexo's stock price today?

One share of HEXO stock can currently be purchased for approximately C$1.00.

How big of a company is Hexo?

Hexo has a market capitalization of C$407.86 million and generates C$59.95 million in revenue each year. Hexo employs 374 workers across the globe.

What is Hexo's official website?

The official website for Hexo is hexo.com.

How can I contact Hexo?

The company can be reached via phone at 844-406-1852.

This page was last updated on 6/4/2020 by MarketBeat.com Staff